Children with persistent or severe asthma symptoms need medicines to reduce airway inflammation. But a change last week means these medicines are harder to access.
Academic rigor, journalistic flair
Articles on PBS pricing
Displaying all articles
The government has missed a chance to better target cost cuts to certain patient groups, for certain medical conditions, and for generic drugs.
The EU is asking Australia to extend drug company monopolies. This could mean Australians wait longer for access to cheaper, generic medicines.
It’s exciting to think we’re on the brink of a genomic revolution in health care. But just because new technology becomes available, it doesn’t mean it should automatically be publicly funded.
A Grattan Institute report released today, Cutting a better drug deal, calls for a major shake-up of pharmacies and pharmaceutical pricing.
Top contributors
-
Honorary Enterprise Professor, School of Population and Global Health, and Department of General Practice and Primary Care, The University of Melbourne
-
Professor of Health Economics and Director, Centre for Health Economics Research and Evaluation, University of Technology Sydney
-
Associate Professor in Public Health, La Trobe University
-
Professor of Health Economics, University of Technology Sydney
-
Honarary Associate Professor; economics of patents, copyright and other "IP", Australian National University
-
Research Fellow, NHMRC Centre for Research Excellence in the Social Determinants of Health Equity, School of Regulation and Global Governance, Australian National University
-
Senior Conjoint Lecturer, UNSW Sydney
-
Clinician Scientist Fellow; Paediatric Respiratory Specialist, Murdoch Children's Research Institute
-
Brett Montgomery is a Friend of The Conversation.
Senior Lecturer in General Practice, The University of Western Australia
-
Professor of Health Economics, The University of Melbourne
